Business
ASX 200 rises 0.5%, Mesoblast plunges – Motley Fool Australia
The S&P/ASX 200 Index (ASX:XJO) went up 0.5% today, with the Mesoblast Limited (ASX:MSB) share price plunging 30.6% on FDA news.
The S&P/ASX 200 Index (ASX: XJO) rose by almost 0.5% today with the ASX continuing to climb.
There was one major plunge on the ASX:
Mesoblast Limited (ASX: MSB) share price crashes lower by 30.6%
Mesoblast released an announcement today on the scheduled meeting of the Oncologic Drugs Advisory Committee (ODAC) of the US FDA for the approval of Ryoncil in the treatment of steroid-refractory acute graft versus host disease in children.
The meeting is scheduled to take place on 13 August 202…
-
Noosa News20 hours agoYoung voices shape Sunshine Coast’s future
-
Business19 hours ago2 Low Cost Active ASX ETFs to consider
-
Noosa News18 hours agoAnother All-Star Cast, Another Tale of Family Chaos: The Trailer for Wes Anderson’s ‘The Phoenician Scheme’ Is Here
-
Business16 hours agoshould I buy hedged or unhedged ASX US-focused ETFs?